Dilutive $5.5M private placement sparks after-hours reversal in AKTX after data-fueled surge
- AKTX surged +255% intraday May 22 to close ~$18.27 (high $18.99) on May 21 preclinical data showing AKTX-101 ADC synergistic with KRAS inhibitors in pancreatic cancer models (ASCO abstract)
- Same-day $5.5M private placement priced at $3.74/ADS (1.47M shares + multiple series of warrants potentially adding >4M more shares) introduced heavy dilution for microcap biotech
- Recent 10-Q revealed $3.7M non-cash impairment on AKTX-101 IPR&D asset itself plus $8.4M goodwill write-down, plus delayed filing and going-concern notes
- Parabolic low-float move (volume >31M shares vs avg ~100K) typical of momentum biotechs led to profit-taking and skepticism over financing timing relative to positive news
- After-hours quote fell to $13.61 (-25.5% from close) with no new press release; reversal reflects digestion of full news package including dilution and impairments
- TipRanks note on risk of further IPR&D write-downs circulated near announcement, underscoring financial pressures despite preclinical KRAS synergy data
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.